
Cyril B. DoussonAi-biopharma · Medicinal Chemistry & Chemoinformatics
Cyril B. Dousson
PhD
Ai-biopharma
About
83
Publications
4,302
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
754
Citations
Introduction
Research and development of new Antiviral candidate drugs (HBV & Coronavirus), Drug Discovery, Medicinal Chemistry, Artificial Intelligence & Chemoinformatic.
Additional affiliations
February 2018 - present
Ai-biopharma
Position
- CEO
Description
- www.ai-biopharma.com
August 2014 - January 2018
August 2003 - August 2014
Education
September 1997 - November 2000
Publications
Publications (83)
Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by nucleos(t)ide analogs (NAs) that profoundly but incompletely suppress DNA synthesis by the viral reverse transcriptase. Residual HBV replication during NA therapy contributes to maintenance of the crit...
Here, we describe the design, synthesis, biological evaluation and identification of a clinical candidate non-nucleoside reverse transcriptase inhibitors (NNRTIs) with a novel Aryl-Phospho-Indole (APhI) scaffold. NNRTIs are recommended components of highly active antiretroviral therapy (HAART) for the treatment of HIV-1. Since a major problem assoc...
This review describes the current state of discovery of past most important nucleoside and nucleotide prodrugs in the treatment of hepatitis C virus infection as well as future potential drugs currently in discovery or clinical evaluation. I highlight first generation landmark prodrug compounds which have been the foundations of incremental improve...
MK-8591 (4’-ethynyl-2-fluoro-2’-deoxyadenosine) is a novel nucleoside analog that displays a differentiated mechanism of action as a nucleoside reverse transcriptase translocation inhibitor (NRTTI) compared to approved NRTIs. Herein, we describe our recent efforts to explore the impact of structural changes to the properties of MK-8591 through the...
In worldwide clinical settings, several nucleos(t)ide analogues
(NAs), including tenofovir disoproxil fumarate (TDF), entecavir
(ETV), and tenofovir alafenamide fumarate (TAF) are used to
treat patients chronically infected with HBV.1,2 NAs are easily
administrated orally and have favorable pharmacologic profiles.3
Their use is generally preferred...
A highly diastereoselective chloride-mediated dynamic kinetic resolution at phosphorus has been developed to access a key intermediate in the synthesis of GSK2248761A. This procedure utilises a soluble chloride source and a cheap readily available chiral auxiliary. The practicality of this transformation is demonstrated on a multi-gram scale.
A new and improved synthetic route to an intermediate in the synthesis of the phosphinate ester GSK2248761A is described. In the key step, we describe the first process-scale example of a palladium-catalyzed phosphorus–carbon coupling to give the entire backbone of GSK2248761A in one telescoped stage in 65% average yield on a 68 kg scale. This unus...
Hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) plays a central role in virus replication. NS5B has no functional equivalent in mammalian cells, and as a consequence is an attractive target for selective inhibition. This paper describes the discovery of a novel family of HCV NS5B non-nucleoside inhibitors inspired by the bioisoster...
Novel liver-targeted antimetabolic pronucleotide for advanced, second-line hepatocellular carcinoma and liver metastasis
Two new methods for the preparation of 1,5,2-diazaphosphinines are described. The first approach involves the reaction between an amidine and an alkynylphosphonate in basic media. The second route involves the reaction between an amidine and a dithioketene acetal phosphonate in basic media. The 1,5,2-diazaphosphinines targets were synthesised for a...
Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for...
Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
http://www.journal-of-hepatology.eu/article/S0168-8278(11)60817-9/pdf
A novel series of 3-aryl-phospho-indole (API) non-nucleoside reverse transcriptase inhibitors of HIV-1 was developed. Chemical variation in the phosphorus linker led to the discovery of 3-phenyl-methyl-phosphinate-2-carboxamide 14, which possessed excellent potency against wild-type HIV-1 as well as viruses bearing K103N and Y181C single mutants in...
The Aurora kinases have been the subject of considerable interest as targets for the development of new anticancer agents. While evidence suggests inhibition of Aurora B kinase gives rise to the more pronounced antiproliferative phenotype, the most clinically advanced agents reported to date typically inhibit both Aurora A and B. We have discovered...
The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory...
An efficient large-scale synthesis of 5-aminopyrimidine derivatives is described. The dihexafluorophosphate salt of a vinamidinium cation important in 5-aminopyrimidine synthesis has been prepared as a stable, easily purified intermediate. It has been used to prepare several 2-functionalized aminopyrimidines, valuable as synthetic building blocks.
An efficient large-scale synthesis of 5-aminopyrimidine derivatives is described. The dihexafluorophosphate salt of a vinamidinium cation important in 5-aminopyrimidine synthesis has been prepared as a stable, easily purified intermediate. It has been used to prepare several 2-functionalized aminopyrimidines, valuable as synthetic building blocks.
A three step synthesis leading to the title compound in good overall yield is described. The bicyclo[3.2.0]heptane framework was formed with good stereocontrol by [ π 2s + π 2a] thermal cycloaddition of the readily available phthalimidoketene with cyclopentadiene. The racemic bicyclic β-amino alcohol 4 was conveniently obtained by mild cleavage of...
The bicyclic alcohol (−)-4 was prepared from (−)-bicyclo[3.2.0]hept-2-en-6-one (−)-1 in 50% yield. The diol (−)-4 was coupled to selected chlorophosphines 6–12 to produce a series of bisphosphinites 13–19 in 89–95% yield. From these bisphosphinites were prepared the rhodium complexes 20–26 which were characterised by 31P NMR and used in situ for th...